Ocugen and Roots Pharmaceutical Complete OCU400 License Agreement for MENA
The companies completed a license agreement for OCU400 modifier gene therapy for retinitis pigmentosa in the Middle East and North Africa.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.